Abstract
Presently the development of TB treatment regimens is aimed at systematization, standardization, and development of a unified approach to treatment throughout the country. TB treatment is difficult due to the proliferation of drug resistant mycobacteria. Drug resistance rates vary and depend on laboratory capacities in the region. The choice of a chemotherapy regimen is associated with the implementation of molecular genetic diagnostic methods, which allow drug resistance determination before treatment. According to the new clinical recommendations, some changes in chemotherapy regimens have been introduced. Treatment for pulmonary TB with multiple, pre-extensive, or extensive drug resistance (MDR, pre-XDR, or XDR) is significantly complicated. The article outlines issues of treatment tactics during the intensive phase of treatment of new pulmonary TB patients on the example of a TB dispensary with a well-equipped laboratory service.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
